Dataset Information

Factors and costs associated with removal of a newly established population of invasive wild pigs in Northern U.S.

ABSTRACT: The human-mediated spread of exotic and invasive species often leads to unintentional and harmful consequences. Invasive wild pigs (Sus scrofa) are one such species that have been repeatedly translocated throughout the United States and cause extensive damage to natural ecosystems, threatened and endangered species, agricultural resources, and private lands. In 2005, a newly established population of wild pigs was confirmed in Fulton County, Illinois, U.S. In 2011, a state-wide wild pig damage management program involving federal, state, and local government authorities directed a concerted effort to remove wild pigs from the county until the last wild pig (of 376 total) was successfully removed in 2016. We examined surveillance data from camera traps at bait sites and records of wild pig removals during this elimination program to identify environmental and anthropogenic factors that optimized removal of this population. Our results revealed that wild pigs used bait sites most during evening and nocturnal periods and on days with lower daily maximum temperatures. Increased removals of wild pigs coincided with periods of cold weather. We also identified that fidelity and time spent at bait sites by wild pigs was not influenced by increasing removals of wild pigs. Finally, the costs to remove wild pigs averaged $50 per wild pig (6.8 effort hours per wild pig) for removing the first 99% of the animals. Cost for removing the last 1% increased 84-fold, and averaged 122.8 effort hours per wild pig removed. Our results demonstrated that increased effort in removing wild pigs using bait sites should be focused during periods of environmental stress to maximize removal efficiency. These results inform elimination programs attempting to remove newly established populations of wild pigs, and ultimately prevent population and geographic expansion.

SUBMITTER: Fischer JW

PROVIDER: S-EPMC7359029 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BackgroundMucosal melanoma has characteristically distinct genetic features and typically poor prognosis. The lack of representative mucosal melanoma models, especially cell lines, has hindered translational research on this melanoma subtype. In this study, we aimed to establish and provide the biological properties, genomic features and the pharmacological profiles of a mucosal melanoma cell line that would contribute to the understanding and treatment optimization of molecularly-defined mucosal melanoma subtype.MethodsThe sample was collected from a 67-year-old mucosal melanoma patient and processed into pieces for the establishment of cell line and patient-derived xenograft (PDX) model. The proliferation and tumorigenic property of cancer cells from different passages were evaluated, and whole-genome sequencing (WGS) was performed on the original tumor, PDX, established cell line, and the matched blood to confirm the establishment and define the genomic features of this cell line. AmpliconArchitect was conducted to depict the architecture of amplified regions detected by WGS. High-throughput drug screening (HTDS) assay including a total of 103 therapeutic agents was implemented on the established cell line, and selected candidate agents were validated in the corresponding PDX model.ResultsA mucosal melanoma cell line, MM9H-1, was established which exhibited robust proliferation and tumorigenicity after more than 100 serial passages. Genomic analysis of MM9H-1, corresponding PDX, and the original tumor showed genetic fidelity across genomes, and MM9H-1 was defined as a triple wild-type (TWT) melanoma subtype lacking well-characterized "driver mutations". Instead, the amplification of several oncogenes, telomerase reverse transcriptase (TERT), v-Raf murine sarcoma viral oncogene homolog B1 (BRAF), melanocyte Inducing transcription factor (MITF) and INO80 complex ATPase subunit (INO80), via large-scale genomic rearrangement potentially contributed to oncogenesis of MM9H-1. Moreover, HTDS identified proteasome inhibitors, especially bortezomib, as promising therapeutic candidates for MM9H-1, which was verified in the corresponding PDX model in vivo.ConclusionsWe established and characterized a new mucosal melanoma cell line, MM9H-1, and defined this cell line as a TWT melanoma subtype lacking well-characterized "driver mutations". The MM9H-1 cell line could be adopted as a unique model for the preclinical investigation of mucosal melanoma.

Dataset Information

Factors and costs associated with removal of a newly established population of invasive wild pigs in Northern U.S.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets